UK Meningococcal Vaccines Market

ID: MRFR/Pharma/51385-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
UK Meningococcal Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines, Conjugate Vaccines), By Age Group (Infants, Children, Adolescents, Adults), By Administration Route (Intramuscular, Subcutaneous, Oral) and By Distribution Channel (Hospitals, Clinics, Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035
UK Meningococcal Vaccines Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.48%
2024 Market Size$ 206.55 Million
2025 Market Size$ 214.47 Million
2035 Market Size$ 301.05 Million
Key Players
GlaxoSmithKline
Pfizer
Sanofi
Merck & Co.
Novartis
Baxter International
Trends
  • Increased Public Awareness
  • Technological Advancements in Vaccines
  • Targeted Vaccination Programs
Opportunities
  • Public Health Campaigns
  • Increased Government Initiatives
  • Advancements in Vaccine Technology
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Vaccination Programs
      2. 4.1.2 Travel Vaccination
      3. 4.1.3 Routine Immunization
      4. 4.1.4 Outbreak Response
      5. 4.1.5 Post-Exposure Prophylaxis
    2. 4.2 Healthcare, BY Age Group (USD Million)
      1. 4.2.1 Infants
      2. 4.2.2 Children
      3. 4.2.3 Adolescents
      4. 4.2.4 Adults
      5. 4.2.5 Elderly
    3. 4.3 Healthcare, BY Type of Vaccine (USD Million)
      1. 4.3.1 Conjugate Vaccine
      2. 4.3.2 Polysaccharide Vaccine
      3. 4.3.3 Recombinant Vaccine
      4. 4.3.4 Combination Vaccine
    4. 4.4 Healthcare, BY Distribution Channel (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Pharmacies
      3. 4.4.3 Clinics
      4. 4.4.4 Public Health Organizations
    5. 4.5 Healthcare, BY End User (USD Million)
      1. 4.5.1 Healthcare Providers
      2. 4.5.2 Government Agencies
      3. 4.5.3 Non-Governmental Organizations
      4. 4.5.4 Educational Institutions
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 GlaxoSmithKline (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Pfizer (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Sanofi (FR)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co. (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Novartis (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Baxter International (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Serum Institute of India (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY APPLICATION
    3. 6.3 UK MARKET ANALYSIS BY AGE GROUP
    4. 6.4 UK MARKET ANALYSIS BY TYPE OF VACCINE
    5. 6.5 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 UK MARKET ANALYSIS BY END USER
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TYPE OF VACCINE, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TYPE OF VACCINE, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY END USER, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY AGE GROUP, 2026-2035 (USD Million)
      3. 7.2.3 BY TYPE OF VACCINE, 2026-2035 (USD Million)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
      5. 7.2.5 BY END USER, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Meningococcal Vaccines Market Segmentation

UK Meningococcal Vaccines Market By Application (USD Million, 2026-2035)

  • Vaccination Programs
  • Travel Vaccination
  • Routine Immunization
  • Outbreak Response
  • Post-Exposure Prophylaxis

UK Meningococcal Vaccines Market By Age Group (USD Million, 2026-2035)

  • Infants
  • Children
  • Adolescents
  • Adults
  • Elderly

UK Meningococcal Vaccines Market By Type of Vaccine (USD Million, 2026-2035)

  • Conjugate Vaccine
  • Polysaccharide Vaccine
  • Recombinant Vaccine
  • Combination Vaccine

UK Meningococcal Vaccines Market By Distribution Channel (USD Million, 2026-2035)

  • Hospitals
  • Pharmacies
  • Clinics
  • Public Health Organizations

UK Meningococcal Vaccines Market By End User (USD Million, 2026-2035)

  • UK Meningococcal Vaccines Market Providers
  • Government Agencies
  • Non-Governmental Organizations
  • Educational Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.